Sign In
Buy BEAM
$25.52
-0.97 (-3.66%)
At Close: Jul 31, 2026
Beam Therapeutics Inc. (BEAM) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
12:46pm, Tuesday, 28'th Oct 2025
Beam Therapeutics (BEAM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Beam Therapeutics: SCD Catalysts Have Untapped Upside Potential
10:19am, Wednesday, 22'nd Oct 2025
Beam Therapeutics Inc.'s base editing platform with BEAM-101 have trait-like hematology and RMAT/ODD designations. BEAM thinks this could eventually position it with a potential best-in-class SCD drug
Beam Therapeutics Inc. (BEAM)'s Technical Outlook is Bright After Key Golden Cross
10:56am, Monday, 20'th Oct 2025
From a technical perspective, Beam Therapeutics Inc. (BEAM) is looking like an interesting pick, as it just reached a key level of support. BEAM's 50-day simple moving average crossed above its 200-da
Wall Street Analysts Think Beam Therapeutics (BEAM) Could Surge 76.15%: Read This Before Placing a Bet
10:56am, Friday, 17'th Oct 2025
The mean of analysts' price targets for Beam Therapeutics (BEAM) points to a 76.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement amon
Is Beam Therapeutics (BEAM) Stock Outpacing Its Medical Peers This Year?
10:41am, Friday, 17'th Oct 2025
Here is how Beam Therapeutics Inc. (BEAM) and Humana (HUM) have performed compared to their sector so far this year.
Top Stock Pick Report: A Q3 For the Record Books
12:25pm, Tuesday, 07'th Oct 2025
Subscribers to Chart of the Week received this commentary on Sunday, October 5.
JIM BEAM AND THE CADILLAC FORMULA 1® TEAM ANNOUNCE GLOBAL PARTNERSHIP, FUELING A VISION TO REACH NEW AUDIENCES
07:00am, Wednesday, 17'th Sep 2025
Two American originals united on one world stage CLERMONT, Ky. and FISHERS, Ind.
Beam Therapeutics Inc. (BEAM) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript
04:51am, Tuesday, 09'th Sep 2025
Beam Therapeutics Inc. (NASDAQ:BEAM ) H.C. Wainwright 27th Annual Global Investment Conference September 8, 2025 10:30 AM EDT Company Participants John Evans - CEO & Director Conference Call Participa
Beam Therapeutics Inc. (BEAM) Presents At Citi's Biopharma Back To School Conference Transcript
08:38pm, Wednesday, 03'rd Sep 2025
Beam Therapeutics Inc. (NASDAQ:BEAM ) Citi's Biopharma Back to School Conference September 3, 2025 4:00 PM EDT Company Participants John Evans - CEO & Director Conference Call Participants Samantha Se
CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now?
09:51am, Thursday, 28'th Aug 2025
CRISPR Therapeutics gains momentum with Casgevy sales and a broader pipeline, while Beam Therapeutics advances base-editing therapies still in early stages.
Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences
07:00am, Monday, 25'th Aug 2025
CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that man
CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the
BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark
12:56pm, Wednesday, 06'th Aug 2025
Beam Therapeutics posts narrower second-quarter loss but misses revenue estimates. The company provides updates on pipeline progress.
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates
09:16am, Tuesday, 05'th Aug 2025
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to a loss of $1.11 per share a year ago.
With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile
